Breaking News Instant updates and real-time market news.

CELC

Celcuity

$13.60 /

-0.35 (-2.51%)

09:35
12/10/21
12/10
09:35
12/10/21
09:35

Celcuity presents results of Phase 1b study of gedatolisib with palbociclib

Celcuity presented a poster at the 2021 San Antonio Breast Cancer Symposium with updated results from a four-arm Phase 1b expansion study. This study evaluated gedatolisib, a first-in-class pan-PI3K/mTOR inhibitor, in combination with palbociclib, a CDK4/6 inhibitor and endocrine therapy in women with ER+/HER2- advanced breast cancer. The poster presented data as of a May 10, 2021 data cutoff. Preliminary data from this Phase 1b study was presented earlier this year with results as of a January 11, 2021 data cut-off. Consistent with the previously released results, the addition of gedatolisib to palbociclib and endocrine therapy demonstrated promising antitumor activity in both first and later line settings for ER+/HER2- ABC that compared favorably to historical controls. A significant objective response rate was also observed in patients refractory to their last treatment or who had received two or more lines of prior treatment for advanced breast cancer. Gedatolisib was well tolerated with manageable toxicity and a low number of patients discontinued treatment due to an adverse event. Phase 1B Study Design and Results: Patients with ER+/HER2- advanced breast cancer were treated in one of four arms. Palbociclib, letrozole, and fulvestrant were administered at standard doses. Gedatolisib 180 mg was intravenously administered weekly in Arms A, B, and C and three weeks on/one week off in Arm D. The primary endpoint was ORR and secondary endpoints were safety, duration of response, and progression free survival. Patient assessment was conducted by the investigator. A summary of key results follows below: Arm A: Patients who were treatment naive in the ABC setting: ORR: 85%; PFS: 31.1 months. Arm B: Patients who received prior endocrine therapy without a CDK4/6 inhibitor: ORR: 77%; PFS: 11.9 months. Arm C: Patients who received prior treatment with a CDK4/6 inhibitor; greater than2 prior therapies for ABC: 66% of patients; ORR: 32%; PFS: 5.1 months. Arm D - Patients who received prior treatment with a CDK4/6 inhibitor; greater than 2 prior therapies for ABC: 33% of patients; ORR: 63%; PFS: 12.9 months. Results from an exploratory comparative and a longitudinal intrapatient analysis were also presented for two sub-groups of Arm C and Arm D patients: patients who had the same number of prior lines of treatment; and patients who had similar durations of treatment with their immediate prior therapy. The two analyses were performed to isolate the effect of the different gedatolisib schedules used in Arm C and Arm D on patient response. Key findings from the analyses are presented below: The ORR in Arm D relative to Arm C was superior irrespective of the number of prior therapies for ABC. Patients who had received one prior line of therapy were 1.7 times more likely to report an objective response in Arm D than Arm C. Patients who had received 2 or more prior lines of therapy were 2.4 times more likely to report an objective response in Arm D than Arm C. The median duration of treatment with gedatolisib was significantly longer in Arm D relative to Arm C, irrespective of the treatment period of their immediate prior therapy. For patients who had progressed on their prior treatment in less than six months, the median duration of treatment for Arm D patients was 3.33 times longer than patients in Arm C. The ORR for this sub-group of Arm D and C patients was 71% and 0% respectively. For patients who had progressed on their prior treatment in less than 12 months, Arm D patients remained on treatment 2.10 times longer than patients in Arm C. The ORR for this sub-group of Arm D and C patients was 73% and 15% respectively. Because duration of treatment tends to decline in subsequent lines of therapy, a longitudinal intrapatient analysis was performed to compare the efficacy of the gedatolisib regimen to the immediate prior regimen for the sub-group of Arm C and D patients who remained on their prior therapy less than six and 12 months. The analysis was performed using duration of treatment because progression free survival data was not available for patients' immediate prior therapy. For Arm D patients who progressed on their prior therapy in less than six months, the median duration of gedatolisib treatment was 2.6 times longer than their immediate prior treatment period. For Arm C patients, the ratio between the time on gedatolisib versus immediate prior therapy was 0.8. For Arm D patients who had progressed on prior therapy in less than 12 months, the median duration of gedatolisib treatment was 1.8 times longer than their immediate prior treatment period. For Arm C patients, the ratio between time on gedatolisib versus immediate prior therapy duration was 0.9. Overall, this exploratory analysis of ORR and duration of treatment found significantly higher ORR and longer duration of treatment in Arm D vs. Arm C patients who progressed within six months and within 12 months on their prior therapy. In addition, ORR was superior in Arm D relative to Arm C in patients irrespective of the number of prior therapies for ABC. This suggests that Arm D's gedatolisib/palbociclib synchronized dosing schedule may have played a significant role in the different outcomes between the Arms. The study of gedatolisib in combination with palbociclib and endocrine therapy also demonstrated that the treatment was well tolerated with side effects managed by available standards of care. No Grade 5 event occurred; the most common Grade 3-4 adverse events were stomatitis and neutropenia. Less than 10% of all patients, and only one patient in Arm D, discontinued treatment due to an adverse event. Fewer patients experienced Grade 3-4 adverse events associated with PI3K/mTOR inhibition compared to data reported for other products in this class. Across all study arms, Grade 3-4 hyperglycemia was observed in less than or equal to7% of patients, AST and ALT elevation in less than or equal to10% of patients, diarrhea and colitis in less than or equal to7% of patients, pneumonitis in less than or equal to4% of patients. These results reflect gedatolisib's differentiated pharmacokinetic properties and indicate that gedatolisib can be safely combined with other targeted agents.

  • 24

    Feb

  • 29

    Jun

OTHER BREAKING NEWS FROM THE FLY

On The Fly
Fly Intel: After-Hours Movers » 18:38
12/06/22
12/06
18:38
12/06/22
18:38
MDB

MongoDB

$144.73 /

-4 (-2.69%)

, GWRE

Guidewire

$56.67 /

-1.08 (-1.87%)

, CASY

Casey's General Stores

$230.07 /

-0.765 (-0.33%)

, SWBI

Smith & Wesson Brands

$11.80 /

-0.275 (-2.28%)

, SKIL

Skillsoft

$1.93 /

-0.06 (-3.02%)

, ZUO

Zuora

$7.20 /

-0.18 (-2.44%)

, HQY

HealthEquity

$65.82 /

-1.915 (-2.83%)

, PLAY

Dave & Buster's

$36.14 /

-1.115 (-2.99%)

, AVAV

AeroVironment

$85.20 /

-3.92 (-4.40%)

, SFIX

Stitch Fix

$3.66 /

-0.375 (-9.29%)

, TOL

Toll Brothers

$45.82 /

-1.09 (-2.32%)

, NBIX

Neurocrine

$120.26 /

-3.4 (-2.75%)

Check out this evening's…

ShowHide Related Items >><<
MDB MongoDB
$144.73 /

-4 (-2.69%)

GWRE Guidewire
$56.67 /

-1.08 (-1.87%)

CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SKIL Skillsoft
$1.93 /

-0.06 (-3.02%)

ZUO Zuora
$7.20 /

-0.18 (-2.44%)

HQY HealthEquity
$65.82 /

-1.915 (-2.83%)

PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

AVAV AeroVironment
$85.20 /

-3.92 (-4.40%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

NBIX Neurocrine
$120.26 /

-3.4 (-2.75%)

MDB MongoDB
$144.73 /

-4 (-2.69%)

12/05/22 Baird
MongoDB price target lowered to $205 from $330 at Baird
11/29/22 UBS
MongoDB price target lowered to $200 from $390 at UBS
11/21/22 Morgan Stanley
MongoDB downgraded at Morgan Stanley amid challenging spending environment
11/21/22 KeyBanc
MongoDB initiated with an Overweight at KeyBanc
GWRE Guidewire
$56.67 /

-1.08 (-1.87%)

12/01/22 DA Davidson
Guidewire price target lowered to $90 from $96 at DA Davidson
12/01/22 JPMorgan
Guidewire initiated with an Overweight at JPMorgan
09/12/22 Citi
Guidewire price target lowered to $79 from $88 at Citi
09/08/22 Baird
Guidewire price target lowered to $81 from $99 at Baird
CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

11/30/22 Wells Fargo
Casey's General Stores price target raised to $260 from $245 at Wells Fargo
11/29/22 Deutsche Bank
Casey's General Stores price target raised to $286 from $269 at Deutsche Bank
09/09/22 Deutsche Bank
Casey's General Stores price target lowered to $269 from $276 at Deutsche Bank
09/09/22 BMO Capital
Casey's General Stores price target raised to $250 from $235 at BMO Capital
SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

09/09/22 Lake Street
Smith & Wesson Brands price target lowered to $22 from $26 at Lake Street
SKIL Skillsoft
$1.93 /

-0.06 (-3.02%)

10/12/22 Citi
Skillsoft price target lowered to $4.50 from $13.50 at Citi
09/08/22 DA Davidson
Skillsoft price target lowered to $3 from $7 at DA Davidson
09/06/22 B. Riley
Skillsoft price target lowered to $6 from $11 at B. Riley
07/26/22 Oppenheimer
Skillsoft assumed with a Perform at Oppenheimer
ZUO Zuora
$7.20 /

-0.18 (-2.44%)

11/28/22 Needham
Needham adds HubSpot to Conviction List, removes Zuora
10/21/22 Goldman Sachs
Zuora initiated with a Neutral at Goldman Sachs
08/25/22 Needham
Zuora price target lowered to $15 from $24 at Needham
08/25/22 Craig-Hallum
Zuora price target lowered to $16 from $22 at Craig-Hallum
HQY HealthEquity
$65.82 /

-1.915 (-2.83%)

12/05/22 RBC Capital
HealthEquity price target raised to $75 from $70 at RBC Capital
11/02/22 Jefferies
HealthEquity price target raised to $90 from $80 at Jefferies
10/21/22 Goldman Sachs
HealthEquity upgraded to Neutral from Sell at Goldman Sachs
10/11/22 BofA
AdaptHealth, HealthEquity, ViaSat added to 'Endeavor List' at BofA
PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

11/08/22 Deutsche Bank
Dave & Buster's upgraded to Buy from Hold at Deutsche Bank
10/05/22 Piper Sandler
Dave & Buster's price target lowered to $34 from $44 at Piper Sandler
09/09/22 Deutsche Bank
Dave & Buster's price target raised to $48 from $37 at Deutsche Bank
09/08/22 Truist
Dave & Buster's price target raised to $62 from $57 at Truist
AVAV AeroVironment
$85.20 /

-3.92 (-4.40%)

11/18/22 Canaccord
AeroVironment price target raised to $105 from $100 at Canaccord
11/10/22 Raymond James
AeroVironment upgraded to Outperform from Market Perform at Raymond James
11/10/22 Raymond James
AeroVironment upgraded to Outperform from Market Perform at Raymond James
09/30/22 RBC Capital
AeroVironment offers best small-cap exposure to Ukraine war, says RBC Capital
SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

09/22/22 Barclays
Stitch Fix price target lowered to $5 from $7 at Barclays
09/21/22 Truist
Stitch Fix price target lowered to $6 from $8 at Truist
09/21/22 Evercore ISI
Stitch Fix price target lowered to $7 from $10 at Evercore ISI
09/21/22 MKM Partners
Stitch Fix price target lowered to $5 from $6 at MKM Partners
TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

11/22/22 JPMorgan
Toll Brothers upgraded to Overweight from Neutral at JPMorgan
10/21/22 Raymond James
Toll Brothers downgraded to Market Perform from Outperform at Raymond James
10/21/22 Raymond James
Toll Brothers downgraded to Market Perform from Outperform at Raymond James
09/19/22 KeyBanc
KeyBanc more bullish on homebuilder names, upgrades five stocks to Overweight
NBIX Neurocrine
$120.26 /

-3.4 (-2.75%)

11/14/22 Evercore ISI
Neurocrine downgraded to In Line from Outperform at Evercore ISI
11/02/22 BMO Capital
Neurocrine price target raised to $101 from $78 at BMO Capital
11/02/22 Wells Fargo
Neurocrine price target raised to $120 from $110 at Wells Fargo
11/02/22 RBC Capital
Neurocrine price target raised to $117 from $101 at RBC Capital
MDB MongoDB
$144.73 /

-4 (-2.69%)

GWRE Guidewire
$56.67 /

-1.08 (-1.87%)

CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SKIL Skillsoft
$1.93 /

-0.06 (-3.02%)

ZUO Zuora
$7.20 /

-0.18 (-2.44%)

HQY HealthEquity
$65.82 /

-1.915 (-2.83%)

PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

AVAV AeroVironment
$85.20 /

-3.92 (-4.40%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

NBIX Neurocrine
$120.26 /

-3.4 (-2.75%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

MDB MongoDB
$144.73 /

-4 (-2.69%)

GWRE Guidewire
$56.67 /

-1.08 (-1.87%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

SKIL Skillsoft
$1.93 /

-0.06 (-3.02%)

ZUO Zuora
$7.20 /

-0.18 (-2.44%)

HQY HealthEquity
$65.82 /

-1.915 (-2.83%)

PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

AVAV AeroVironment
$85.20 /

-3.92 (-4.40%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

NBIX Neurocrine
$120.26 /

-3.4 (-2.75%)

MDB MongoDB
$144.73 /

-4 (-2.69%)

SWBI Smith & Wesson Brands
$11.80 /

-0.275 (-2.28%)

ZUO Zuora
$7.20 /

-0.18 (-2.44%)

PLAY Dave & Buster's
$36.14 /

-1.115 (-2.99%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

TOL Toll Brothers
$45.82 /

-1.09 (-2.32%)

Syndicate
X4 Pharmaceuticals announces common stock, warrant offering, no amount given » 18:27
12/06/22
12/06
18:27
12/06/22
18:27
XFOR

X4 Pharmaceuticals

$1.18 /

-0.11 (-8.53%)

X4 Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$1.18 /

-0.11 (-8.53%)

XFOR X4 Pharmaceuticals
$1.18 /

-0.11 (-8.53%)

11/30/22 H.C. Wainwright
X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright
08/05/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $3.50 from $8.50 at H.C. Wainwright
05/19/22 B. Riley
X4 Pharmaceuticals price target lowered to $7 from $10 at B. Riley
05/13/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $8.50 from $11 at H.C. Wainwright
XFOR X4 Pharmaceuticals
$1.18 /

-0.11 (-8.53%)

XFOR X4 Pharmaceuticals
$1.18 /

-0.11 (-8.53%)

Hot Stocks
Guaranty Bancshares director Baker buys 21,536 common shares » 18:04
12/06/22
12/06
18:04
12/06/22
18:04
GNTY

Guaranty Bancshares

$34.54 /

-0.06 (-0.17%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GNTY Guaranty Bancshares
$34.54 /

-0.06 (-0.17%)

07/07/22 Raymond James
Guaranty Bancshares downgraded to Market Perform from Outperform at Raymond James
07/07/22 Raymond James
Guaranty Bancshares downgraded to Market Perform from Outperform at Raymond James
GNTY Guaranty Bancshares
$34.54 /

-0.06 (-0.17%)

GNTY Guaranty Bancshares
$34.54 /

-0.06 (-0.17%)

Hot Stocks
MediciNova presents results from subgroup analysis of Phase 2 study of MN-001 » 18:03
12/06/22
12/06
18:03
12/06/22
18:03
MNOV

MediciNova

$2.40 /

-0.09 (-3.61%)

MediciNova announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MNOV MediciNova
$2.40 /

-0.09 (-3.61%)

MNOV MediciNova
$2.40 /

-0.09 (-3.61%)

01/24/22 B. Riley
MediciNova price target lowered to $6 from $11 at B. Riley
MNOV MediciNova
$2.40 /

-0.09 (-3.61%)

Initiation
Argenx initiated with an Outperform at William Blair » 17:56
12/06/22
12/06
17:56
12/06/22
17:56
ARGX

Argenx

$384.77 /

-8.435 (-2.15%)

William Blair analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ARGX Argenx
$384.77 /

-8.435 (-2.15%)

ARGX Argenx
$384.77 /

-8.435 (-2.15%)

15:50 Today Barclays
Argenx price target raised to EUR 450 from EUR 405 at Barclays
11/14/22 JPMorgan
Argenx price target raised to EUR 480 from EUR 470 at JPMorgan
10/28/22 H.C. Wainwright
Argenx price target raised to $440 from $425 at H.C. Wainwright
10/27/22 Piper Sandler
Piper Sandler remains a buyer of Argenx after Q3 beat
ARGX Argenx
$384.77 /

-8.435 (-2.15%)

  • 24
    Mar
Downgrade
Gossamer Bio downgraded to Neutral from Outperform at SMBC Nikko » 17:54
12/06/22
12/06
17:54
12/06/22
17:54
GOSS

Gossamer Bio

$2.35 /

-6.97 (-74.79%)

SMBC Nikko analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GOSS Gossamer Bio
$2.35 /

-6.97 (-74.79%)

GOSS Gossamer Bio
$2.35 /

-6.97 (-74.79%)

11:06 Today Piper Sandler
Piper says 'Street overreacted' to Gossamer data, seralutinib still 'promising'
09:45 Today BTIG
Aerovate upgraded to Buy at BTIG after Gossamer study hits endpoint
10/20/22 Goldman Sachs
Gossamer Bio initiated with a Buy at Goldman Sachs
10/13/22 H.C. Wainwright
Gossamer Bio price target raised to $25 from $20 at H.C. Wainwright
GOSS Gossamer Bio
$2.35 /

-6.97 (-74.79%)

GOSS Gossamer Bio
$2.35 /

-6.97 (-74.79%)

Periodicals
U.K. game sales down 7.3% y/y in November, Gamesindustry.biz says » 17:48
12/06/22
12/06
17:48
12/06/22
17:48
ATVI

Activision Blizzard

$76.12 /

-0.215 (-0.28%)

, SONY

Sony

$79.45 /

-2.205 (-2.70%)

, EA

Electronic Arts

$127.44 /

-3 (-2.30%)

, NTDOY

Nintendo

$10.43 /

+0.09 (+0.87%)

, SGAMY

Sega Sammy Holdings

$3.24 /

-0.015 (-0.46%)

More than 4.3M video game…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ATVI Activision Blizzard
$76.12 /

-0.215 (-0.28%)

SONY Sony
$79.45 /

-2.205 (-2.70%)

EA Electronic Arts
$127.44 /

-3 (-2.30%)

NTDOY Nintendo
$10.43 /

+0.09 (+0.87%)

SGAMY Sega Sammy Holdings
$3.24 /

-0.015 (-0.46%)

ATVI Activision Blizzard
$76.12 /

-0.215 (-0.28%)

07:02 Today Edward Jones
Activision Blizzard upgraded to Buy from Hold at Edward Jones
12/01/22 Wedbush
Activision Blizzard added to Best Ideas List at Wedbush
11/28/22 JPMorgan
Activision Blizzard price target lowered to $86 from $95 at JPMorgan
11/28/22 Wells Fargo
Wells Fargo upgrades Activision Blizzard to Overweight with $95 price target
SONY Sony
$79.45 /

-2.205 (-2.70%)

11/02/22 Cowen
Sony price target lowered to $102 from $144 at Cowen
10/13/22 Oppenheimer
Oppenheimer sees more difficulty for Microsoft/Activision to win CMA approval
09/07/22 Goldman Sachs
Sony resumed with a Neutral at Goldman Sachs
07/08/22 Macquarie
Sony upgraded to Outperform, added to 'Marquee Buy' list at Macquarie
EA Electronic Arts
$127.44 /

-3 (-2.30%)

11/28/22 Truist
Electronic Arts price target lowered to $150 from $154 at Truist
11/22/22 Truist
EA's Sports College Football timeline 'consistent' with model, says Truist
11/08/22 Deutsche Bank
Electronic Arts remains top pick in video games at Deutsche Bank
11/02/22 Wedbush
Electronic Arts price target lowered to $164 from $170 at Wedbush
NTDOY Nintendo
$10.43 /

+0.09 (+0.87%)

09/07/22 Goldman Sachs
Nintendo resumed with a Buy at Goldman Sachs
05/24/22 CLSA
Nintendo price target lowered to 51,000 yen from 53,000 yen at CLSA
03/23/22 Macquarie
Nintendo upgraded to Outperform from Neutral at Macquarie
02/16/22 Jefferies
Nintendo upgraded to Buy from Hold at Jefferies
SGAMY Sega Sammy Holdings
$3.24 /

-0.015 (-0.46%)

ATVI Activision Blizzard
$76.12 /

-0.215 (-0.28%)

SONY Sony
$79.45 /

-2.205 (-2.70%)

EA Electronic Arts
$127.44 /

-3 (-2.30%)

NTDOY Nintendo
$10.43 /

+0.09 (+0.87%)

ATVI Activision Blizzard
$76.12 /

-0.215 (-0.28%)

SONY Sony
$79.45 /

-2.205 (-2.70%)

EA Electronic Arts
$127.44 /

-3 (-2.30%)

NTDOY Nintendo
$10.43 /

+0.09 (+0.87%)

SGAMY Sega Sammy Holdings
$3.24 /

-0.015 (-0.46%)

ATVI Activision Blizzard
$76.12 /

-0.215 (-0.28%)

SONY Sony
$79.45 /

-2.205 (-2.70%)

EA Electronic Arts
$127.44 /

-3 (-2.30%)

NTDOY Nintendo
$10.43 /

+0.09 (+0.87%)

SGAMY Sega Sammy Holdings
$3.24 /

-0.015 (-0.46%)

ATVI Activision Blizzard
$76.12 /

-0.215 (-0.28%)

SONY Sony
$79.45 /

-2.205 (-2.70%)

EA Electronic Arts
$127.44 /

-3 (-2.30%)

Hot Stocks
BAE Systems awarded $128.21M Army contract » 17:46
12/06/22
12/06
17:46
12/06/22
17:46
BAESY

BAE Systems

$40.45 /

+0.182 (+0.45%)

BAE Systems was awarded a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BAESY BAE Systems
$40.45 /

+0.182 (+0.45%)

BAESY BAE Systems
$40.45 /

+0.182 (+0.45%)

11/07/22 JPMorgan
BAE Systems price target raised to 1,100 GBp from 1,000 GBp at JPMorgan
11/07/22 Redburn
BAE Systems initiated with a Buy at Redburn
10/07/22 JPMorgan
BAE Systems price target raised to 1,000 GBp from 965 GBp at JPMorgan
08/05/22 Deutsche Bank
BAE Systems price target raised to EUR 970 from EUR 860 at Deutsche Bank
BAESY BAE Systems
$40.45 /

+0.182 (+0.45%)

BAESY BAE Systems
$40.45 /

+0.182 (+0.45%)

Hot Stocks
Bell Textron awarded $1.36B Army contract » 17:44
12/06/22
12/06
17:44
12/06/22
17:44
TXT

Textron

$73.58 /

+3.585 (+5.12%)

Bell Textron was awarded…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TXT Textron
$73.58 /

+3.585 (+5.12%)

TXT Textron
$73.58 /

+3.585 (+5.12%)

09:26 Today Morgan Stanley
Textron's FLRAA win should be 'positively received,' says Morgan Stanley
12/05/22 Jefferies
Textron award estimated at $11 per share net present value, says Jefferies
09/13/22 Bernstein
Textron initiated with a Market Perform at Bernstein
07/29/22 Susquehanna
Textron price target lowered to $84 from $90 at Susquehanna
TXT Textron
$73.58 /

+3.585 (+5.12%)

TXT Textron
$73.58 /

+3.585 (+5.12%)

TXT Textron
$73.58 /

+3.585 (+5.12%)

TXT Textron
$73.58 /

+3.585 (+5.12%)

Hot Stocks
BRT Apartments CEO buys $285K in common stock » 17:40
12/06/22
12/06
17:40
12/06/22
17:40
BRT

BRT Apartments

$19.84 /

+0.04 (+0.20%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BRT BRT Apartments
$19.84 /

+0.04 (+0.20%)

BRT BRT Apartments
$19.84 /

+0.04 (+0.20%)

11/11/22 B. Riley
BRT Apartments price target lowered to $30 from $32 at B. Riley
05/09/22 BTIG
BRT Apartments assumed with a Neutral at BTIG
03/21/22 B. Riley
BRT Apartments upgraded to Buy on strategic shift at B. Riley
03/21/22 B. Riley
BRT Apartments upgraded to Buy from Neutral at B. Riley
BRT BRT Apartments
$19.84 /

+0.04 (+0.20%)

Initiation
Sachem Capital initiated with a Hold at JonesTrading » 17:37
12/06/22
12/06
17:37
12/06/22
17:37
SACH

Sachem Capital

$3.41 /

-0.045 (-1.30%)

JonesTrading analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SACH Sachem Capital
$3.41 /

-0.045 (-1.30%)

SACH Sachem Capital
$3.41 /

-0.045 (-1.30%)

12/05/22 EF Hutton
Sachem Capital assumed with a Buy at EF Hutton
11/14/22 JMP Securities
Sachem Capital initiated with a Market Perform at JMP Securities
04/27/22 Oppenheimer
Sachem Capital initiated with an Outperform at Oppenheimer
SACH Sachem Capital
$3.41 /

-0.045 (-1.30%)

Hot Stocks
Kairos Acquisition announces liquidation » 17:30
12/06/22
12/06
17:30
12/06/22
17:30
KAIR

Kairos Acquisition

$10.07 /

+ (+0.00%)

Kairos Acquisition…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Syndicate
HP Inc. files automatic mixed securities shelf  17:28
12/06/22
12/06
17:28
12/06/22
17:28
HPQ

HP Inc.

$28.31 /

-0.91 (-3.11%)

 
ShowHide Related Items >><<
HPQ HP Inc.
$28.31 /

-0.91 (-3.11%)

HPQ HP Inc.
$28.31 /

-0.91 (-3.11%)

11/23/22 Evercore ISI
Evercore sticking with In Line rating on HP Inc. as company takes 'right steps'
11/23/22 Citi
HP Inc. restructuring 'unexpected major positive,' says Citi
11/23/22 Barclays
HP Inc. price target lowered to $24 from $27 at Barclays
11/18/22 BofA
HP Inc. price target lowered to $27 from $30 at BofA
HPQ HP Inc.
$28.31 /

-0.91 (-3.11%)

HPQ HP Inc.
$28.31 /

-0.91 (-3.11%)

HPQ HP Inc.
$28.31 /

-0.91 (-3.11%)

Hot Stocks
Stitch Fix says will reduce marketing in back half of the year » 17:28
12/06/22
12/06
17:28
12/06/22
17:28
SFIX

Stitch Fix

$3.66 /

-0.375 (-9.29%)

Says retail industry…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

09/22/22 Barclays
Stitch Fix price target lowered to $5 from $7 at Barclays
09/21/22 Truist
Stitch Fix price target lowered to $6 from $8 at Truist
09/21/22 Evercore ISI
Stitch Fix price target lowered to $7 from $10 at Evercore ISI
09/21/22 MKM Partners
Stitch Fix price target lowered to $5 from $6 at MKM Partners
SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

SFIX Stitch Fix
$3.66 /

-0.375 (-9.29%)

Hot Stocks
Pulse Biosciences CFO Sandra Gardiner to resign » 17:27
12/06/22
12/06
17:27
12/06/22
17:27
PLSE

Pulse Biosciences

$2.65 /

+0.44 (+19.91%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PLSE Pulse Biosciences
$2.65 /

+0.44 (+19.91%)

PLSE Pulse Biosciences
$2.65 /

+0.44 (+19.91%)

09/21/22 Maxim
Pulse Biosciences downgraded to Hold from Buy at Maxim
05/13/22 H.C. Wainwright
Pulse Biosciences downgraded to Neutral from Buy at H.C. Wainwright
05/12/22 Stephens
Pulse Biosciences downgraded to Equal Weight from Overweight at Stephens
04/01/22 H.C. Wainwright
Pulse Biosciences price target lowered to $8.50 from $20 at H.C. Wainwright
PLSE Pulse Biosciences
$2.65 /

+0.44 (+19.91%)

Periodicals
Apple CEO Tim Cook reaffirms company will use chips made in Arizona, AI says » 17:25
12/06/22
12/06
17:25
12/06/22
17:25
AAPL

Apple

$142.94 /

-3.67 (-2.50%)

, TSM

TSMC

$79.59 /

-2.06 (-2.52%)

Apple (AAPL) CEO Tim Cook…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AAPL Apple
$142.94 /

-3.67 (-2.50%)

TSM TSMC
$79.59 /

-2.06 (-2.52%)

AAPL Apple
$142.94 /

-3.67 (-2.50%)

11:24 Today UBS
Apple iPhone 14 Pro/Pro Max delivery times finally easing, says UBS
12/05/22 Wedbush
Apple shift out of China will not be easy, says Wedbush
12/02/22 Morgan Stanley
Morgan Stanley sees December quarter App Store forecast as 'conservative'
12/01/22 Piper Sandler
Apple estimates lowered on shutdowns in Zhengzhou at Piper Sandler
TSM TSMC
$79.59 /

-2.06 (-2.52%)

11/18/22 Erste Group
TSMC upgraded to Buy from Hold at Erste Group
11/15/22 Credit Suisse
Intel assumed with a Neutral at Credit Suisse
10/17/22 Northland
Teradyne price target lowered to $74 from $85 at Northland
10/13/22 Goldman Sachs
TSMC downgraded to Buy from Conviction Buy at Goldman Sachs
AAPL Apple
$142.94 /

-3.67 (-2.50%)

TSM TSMC
$79.59 /

-2.06 (-2.52%)

AAPL Apple
$142.94 /

-3.67 (-2.50%)

TSM TSMC
$79.59 /

-2.06 (-2.52%)

AAPL Apple
$142.94 /

-3.67 (-2.50%)

TSM TSMC
$79.59 /

-2.06 (-2.52%)

AAPL Apple
$142.94 /

-3.67 (-2.50%)

TSM TSMC
$79.59 /

-2.06 (-2.52%)

Conference/Events
BTIG medical technology analyst to hold a group dinner » 17:25
12/06/22
12/06
17:25
12/06/22
17:25

Medical Tech &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Recommendations
Airbus price target lowered to EUR 132 from EUR 140 at Jefferies » 17:18
12/06/22
12/06
17:18
12/06/22
17:18
EADSY

Airbus

$28.58 /

-0.185 (-0.64%)

Jefferies analyst Chloe…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EADSY Airbus
$28.58 /

-0.185 (-0.64%)

EADSY Airbus
$28.58 /

-0.185 (-0.64%)

11/07/22 Redburn
Safran initiated with a Buy at Redburn
11/07/22 Redburn
Airbus initiated with a Buy at Redburn
11/01/22 JPMorgan
Airbus price target raised to EUR 185 from EUR 155 at JPMorgan
09/26/22 JPMorgan
Airbus price target lowered to EUR 155 from EUR 175 at JPMorgan
EADSY Airbus
$28.58 /

-0.185 (-0.64%)

EADSY Airbus
$28.58 /

-0.185 (-0.64%)

EADSY Airbus
$28.58 /

-0.185 (-0.64%)

Hot Stocks
Morningstar raises quarterly dividend 4.2%, announces $500M share repurchase » 17:17
12/06/22
12/06
17:17
12/06/22
17:17
MORN

Morningstar

$235.11 /

-8.06 (-3.31%)

The board of directors of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MORN Morningstar
$235.11 /

-8.06 (-3.31%)

MORN Morningstar
$235.11 /

-8.06 (-3.31%)

09/20/22 Redburn
Morningstar upgraded to Buy at Redburn on downturn resilience
09/20/22 Redburn
Morningstar upgraded to Buy from Neutral at Redburn
MORN Morningstar
$235.11 /

-8.06 (-3.31%)

General News
API crude inventories for week of December 2 » 17:13
12/06/22
12/06
17:13
12/06/22
17:13
USO

United States Oil Fund

$65.22 /

-2.495 (-3.68%)

API reports that crude…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
USO United States Oil Fund
$65.22 /

-2.495 (-3.68%)

USO United States Oil Fund
$65.22 /

-2.495 (-3.68%)

USO United States Oil Fund
$65.22 /

-2.495 (-3.68%)

USO United States Oil Fund
$65.22 /

-2.495 (-3.68%)

Hot Stocks
Casey's General Stores sees FY23 same-store inside sales 5%-7%. » 17:11
12/06/22
12/06
17:11
12/06/22
17:11
CASY

Casey's General Stores

$230.07 /

-0.765 (-0.33%)

Due to the strong…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

11/30/22 Wells Fargo
Casey's General Stores price target raised to $260 from $245 at Wells Fargo
11/29/22 Deutsche Bank
Casey's General Stores price target raised to $286 from $269 at Deutsche Bank
09/09/22 Deutsche Bank
Casey's General Stores price target lowered to $269 from $276 at Deutsche Bank
09/09/22 BMO Capital
Casey's General Stores price target raised to $250 from $235 at BMO Capital
CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

Earnings
Casey's General Stores reports Q2 EPS $3.67, consensus $3.16 » 17:08
12/06/22
12/06
17:08
12/06/22
17:08
CASY

Casey's General Stores

$230.07 /

-0.765 (-0.33%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

11/30/22 Wells Fargo
Casey's General Stores price target raised to $260 from $245 at Wells Fargo
11/29/22 Deutsche Bank
Casey's General Stores price target raised to $286 from $269 at Deutsche Bank
09/09/22 Deutsche Bank
Casey's General Stores price target lowered to $269 from $276 at Deutsche Bank
09/09/22 BMO Capital
Casey's General Stores price target raised to $250 from $235 at BMO Capital
CASY Casey's General Stores
$230.07 /

-0.765 (-0.33%)

Hot Stocks
Trustmark announces $50M buyback program » 17:04
12/06/22
12/06
17:04
12/06/22
17:04
TRMK

Trustmark

$34.85 /

-0.05 (-0.14%)

Trustmark "announced…

Trustmark "announced that, effective January 1, 2023, the Board of Directors has authorized a new stock repurchase program under which up to $50,000,000 of its outstanding common shares may be acquired through December 31, 2023. The adoption of the Company's share repurchase program follows the notification of the new share repurchase program by the Company to the Board of Governors of the Federal Reserve System. This authorization replaces the Company's prior stock repurchase program, which will expire in accordance with its terms on December 31, 2022."

ShowHide Related Items >><<
TRMK Trustmark
$34.85 /

-0.05 (-0.14%)

05/02/22 Truist
Trustmark price target lowered to $30 from $35 at Truist
TRMK Trustmark
$34.85 /

-0.05 (-0.14%)

Conference/Events
Compugen to hold a conference call » 17:03
12/06/22
12/06
17:03
12/06/22
17:03
CGEN

Compugen

$1.16 /

+0.065 (+5.96%)

Management discusses the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CGEN Compugen
$1.16 /

+0.065 (+5.96%)

CGEN Compugen
$1.16 /

+0.065 (+5.96%)

11/14/22 Oppenheimer
Compugen price target lowered to $8 from $12 at Oppenheimer
08/23/22 Truist
Compugen price target lowered to $4 from $14 at Truist
08/08/22 JMP Securities
Compugen price target lowered to $4 from $8 at JMP Securities
08/05/22 Jefferies
Jefferies downgrades Compugen to Hold with cash likely becoming 'growing issue'
CGEN Compugen
$1.16 /

+0.065 (+5.96%)

CGEN Compugen
$1.16 /

+0.065 (+5.96%)

Hot Stocks
Butterfly Network CEO Todd Fruchterman to depart, Rothberg named interim CEO » 17:02
12/06/22
12/06
17:02
12/06/22
17:02
BFLY

Butterfly Network

$3.07 /

-0.195 (-5.97%)

Butterfly Network…

Butterfly Network announced that the company and Todd Fruchterman, M.D., Ph.D. have mutually agreed that Dr. Fruchterman will leave his position as President and CEO and as a member of the Board of Directors. Dr. Fruchterman will partner with Butterfly's leadership team through the end of the year to ensure a smooth transition. Dr. Rothberg will serve as Interim CEO during this time of transition and will work closely with Butterfly's executive team to continue to drive the company forward and ensure business continuity during the search for a permanent replacement.

ShowHide Related Items >><<
BFLY Butterfly Network
$3.07 /

-0.195 (-5.97%)

BFLY Butterfly Network
$3.07 /

-0.195 (-5.97%)

11/28/22 Oppenheimer
Butterfly Network initiated with an Outperform at Oppenheimer
10/04/22 B. Riley
B. Riley starts Butterfly Network at Buy on ultrasound potential
10/04/22 B. Riley
Butterfly Network initiated with a Buy at B. Riley
05/11/22 Cowen
Butterfly Network price target lowered to $7 from $12 at Cowen
BFLY Butterfly Network
$3.07 /

-0.195 (-5.97%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.